Thermo Fisher Q2 2026: revenue up 10.0%, adjusted EPS $6.03 beats consensus
The quarter beat: revenue of $11.99 billion rose 10.0% and adjusted EPS of $6.03 topped the $5.77 consensus estimate shown here. The caveats are that only half of the growth was organic, the GAAP-to-adjusted EPS gap is $1.35 a share, and management has not yet put updated 2026 guidance in the release. Read the numbers below with amortization and acquisition spending in mind.
1 · Expected vs. Actual
Free preview belowGAAP diluted EPS was $4.68, up 9.0% from $4.28, while adjusted EPS was $6.03, up 13.0% from $5.36. The adjusted figure is about 4.5% above the $5.77 consensus estimate, so the beat came on the number most analysts track, not on the GAAP line. The $1.35 gap between the two EPS lines is dominated by $1.31 a share of amortization of acquisition-related intangible assets.
Revenue of $11.99 billion rose 10.0% from $10.85 billion a year earlier. Only 5.0% was organic, while acquisitions added 5.0% and currency 1.0%, so half the headline growth was bought rather than earned. Sequentially, revenue rose from $11.01 billion in the first quarter.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-09-17
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.